Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of May 2025, with a report date of May 21, 2025. The filing discloses a material financing transaction entered into on May 17, 2025, involving a bridge loan agreement.
Key Financial Metrics
- Debt Financing: The Company secured an unsecured bridge loan of $2,000,000 from Epoch Partner Investments Limited.
- Interest Rate: Interest accrues at the rate of a 12-month U.S. Treasury bond effective as of May 17, 2025, calculated on a 365-day basis.
- Maturity: The loan is due no later than one calendar year from the effective date (May 17, 2026).
- Liquidity Impact: Proceeds are available for any purpose determined by the Board of Directors.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or operating margins.
Material Changes and Loan Terms
The primary material change is the execution of the $2,000,000 bridge loan. Key terms include:
- Prepayment: The loan may be repaid early without penalty.
- Equity Transaction Linkage: If the Company raises capital via an equity transaction (excluding at-the-market offerings or equity lines), proceeds up to the loan amount must be used for prepayment, subject to the lender's participation.
- Lender Participation: In future equity raises (outside of ATM/equity lines), the lender (Epoch) commits to participating with an amount no less than the outstanding loan balance.
Related Party and Ownership
As of the filing date, Epoch Partner Investments Limited beneficially owns approximately 44% of the Company's issued and outstanding ordinary shares. Mr. Li Haixiang, a director of Icecure Medical Ltd., is the sole director of Epoch and holds voting and dispositive power over Epoch's shares.
Investor Verification Checklist
- Verify the specific interest rate applied based on the 12-month U.S. Treasury bond rate on May 17, 2025.
- Review the full text of the Unsecured Loan Agreement (Exhibit 10.1) for covenants not summarized in this report.
- Monitor future equity financing activities to assess the mandatory prepayment triggers and lender participation requirements.
- Confirm the Company's current cash position and runway given the new debt obligation.